The inhibition of glycogen synthase kinase 3 beta (GSK3β) has consistently provided neuroprotection across varying animal models of AD, with a common protective effect against tau pathologies, as reviewed by Avila and colleagues [98]. Here, MAPT is linked to Alzheimer disease.